动脉门静脉造影术期间的CT：将前列腺素E1预先注入肠系膜上动脉的影响。

CT during arterial portography: effects of precontrast injection of prostaglandin E1 into the superior mesenteric artery.

作者信息

Terada Masaki, Sato Morio, Tanihata Hirohiko, Horihata Koushi, Masuda Mitsunori, Kimura Masashi, Nakai Motoki, Minamiguchi Hiroki, Shirai Shintaro

机构信息

Department of Radiology, Wakayama Medical University, 811-1 Kimiidera Wakayama 641-8510, Japan.

出版信息

J Comput Assist Tomogr. 2002 Nov-Dec;26(6):1022-5. doi: 10.1097/00004728-200211000-00029.

DOI:10.1097/00004728-200211000-00029

PMID:12488754

Abstract

Prostaglandin E1 (PGE1) is a vasodilator that increases portal venous flow. Hepatic CT during arterial portography (CTAP) was performed in 42 patients with and without PGE1 to compare peak hepatic enhancement and nontumorous abnormalities. Although no significant differences in peak hepatic enhancement were observed (71 +/- 12 HU for CTAP with PGE1; 74 +/- 34 HU for CTAP without PGE1), the number of nontumorous abnormalities for CTAP with PGE1 (n = 11) was significantly lower than that for CTAP without PGE1 (n = 24) (p < 0.01, Wilcoxon signed rank test). CTAP combined with PGE1 therefore represents a useful method to study lesions of the liver, as the number of nontumorous abnormalities observed is significantly reduced and liver parenchyma can be scanned more evenly.

摘要

前列腺素E1（PGE1）是一种可增加门静脉血流的血管扩张剂。对42例使用和未使用PGE1的患者进行了动脉门静脉造影期间的肝脏CT检查（CTAP），以比较肝脏强化峰值和非肿瘤性异常情况。尽管未观察到肝脏强化峰值有显著差异（使用PGE1的CTAP为71±12HU；未使用PGE1的CTAP为74±34HU），但使用PGE1的CTAP（n = 11）的非肿瘤性异常数量显著低于未使用PGE1的CTAP（n = 24）（p < 0.01，Wilcoxon符号秩检验）。因此，CTAP联合PGE1是研究肝脏病变的一种有用方法，因为观察到的非肿瘤性异常数量显著减少，并且肝脏实质可以更均匀地扫描。